These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2727988)

  • 1. Establishment of an etoposide (VP-16)-resistant subline of THP-1 human monocytic leukemia cell line.
    Saijo Y; Kumano N; Suzuki S; Koinumaru S; Sugawara S; Oizumi K; Motomiya M
    Tohoku J Exp Med; 1989 Mar; 157(3):215-9. PubMed ID: 2727988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
    Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
    Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of resistance to VP-16 in human leukemic cell line.
    Saijo Y; Kumano N; Tokue Y; Satoh K; Oizumi K; Motomiya M
    Tohoku J Exp Med; 1989 Dec; 159(4):299-306. PubMed ID: 2633408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and properties of vincristine-resistant human myelogenous leukemia K562.
    Tsuruo T; Iida H; Ohkochi E; Tsukagoshi S; Sakurai Y
    Gan; 1983 Oct; 74(5):751-8. PubMed ID: 6580255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
    Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Moritaka T; Tabata M; Segawa Y; Shibayama T; Gemba K; Matsumura T
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):473-7. PubMed ID: 8383949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines.
    Lock RB; Hill BT
    Int J Cancer; 1988 Sep; 42(3):373-81. PubMed ID: 3417366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
    Politi PM; Sinha BK
    Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
    Hong JH
    Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
    Patel S; Austin CA; Fisher LM
    Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric analysis of the cell cycle of the leukemic cell lines treated with etoposide and cytosine arabinoside.
    Ishiyama K; Satoh S; Igarashi Y; Kumagai H; Yahagi A; Sasaki H
    Tohoku J Exp Med; 1994 Oct; 174(2):95-107. PubMed ID: 7900157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.
    Jensen PB; Roed H; Skovsgaard T; Friche E; Vindeløv L; Hansen HH; Spang-Thomsen M
    Cancer Chemother Pharmacol; 1990; 27(3):194-8. PubMed ID: 2265455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
    Ritke MK; Yalowich JC
    Biochem Pharmacol; 1993 Dec; 46(11):2007-20. PubMed ID: 8267650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
    Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
    Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of etoposide (VP-16) and teniposide (VM-26) in exponential and plateau phase human tumor cell cultures.
    Chapuis JC; Keng PC; Siemann DW
    Anticancer Drugs; 1992 Jun; 3(3):245-52. PubMed ID: 1525405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.